Introduction
============

Lung cancer is the leading cause of cancer-related mortality worldwide. In 2012, 1,824,701 new cases were diagnosed, and 1,590,000 patients died of lung cancer globally[@B1]. Although epidemiologic data showed an increasing trend of survival rate of lung cancer, 88,655 patients died from lung cancer in Korea during the period 2008 to 2012[@B2]. Numerous efforts have been made to reduce the mortality of this devastating disease, and we have noticed great progress in the management of lung cancer over the past decades.

Notably, molecular-targeted therapy, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) and anaplastic lymphoma kinase (ALK) inhibitors, has improved the survival of patients with tumors harboring driving genetic alterations[@B3]. In addition, immune checkpoint inhibitors (ICIs) targeting programmed death-l or its ligand (PD-L1) have also shown survival benefit in selected or unselected populations[@B4][@B5][@B6], and are actively under clinical trials. However, only about 15% to 40% of all non-small cell lung cancer (NSCLC) patients have *EGFR* mutation or *ALK* rearrangement[@B7], and only about 30% of the *EGFR* - and *ALK*-negative patients had tumors with PD-L1 tumor proportion score (TPS) of 50% or greater[@B4], which means the rest of the patients are candidates for the first-line platinum-based chemotherapy. Moreover, in the cases of TKIs or ICIs failure, chemotherapy is recommended as a valid subsequent treatment[@B8][@B9][@B10]. In this review, I will discuss current evidence of the clinical benefit of chemotherapy, new treatment strategies, and potential biomarkers after a brief review of the history of development of lung cancer chemotherapy.

Evolution of Chemotherapy in Lung Cancer Therapeutics
=====================================================

Before the chemotherapy era, the median overall survival (OS) of metastatic lung cancer was merely 2 to 4 months with the best supportive care[@B11]. Although early generation chemotherapeutic agents, including methotrexate and doxorubicin, were used for the management of lung cancer in the 1970s, the clinical benefit was modest[@B12]. Substantial survival benefit in lung cancer patients was shown only after the development and introduction of platinum and new generation chemotherapeutic agents, including taxanes, vinorelbine, and gemcitabine, during the 1980s and 1990s. A landmark meta-analysis by the Non-Small Cell Lung Cancer Collaborative Group in 1995 has demonstrated that platinum-based chemotherapy significantly improved OS over the best supportive care (15% vs. 5% OS rate in 1 year)[@B13]. In addition, the platinum doublet showed superior efficacy over non-platinum based regimen or single agent[@B14]. Eastern Cooperative Oncology Group (ECOG) 1594 trial prospectively compared four platinum-based doublets for advanced NSCLC, and demonstrated that survival was not different among different regimens with median OS of 7.9 months, and good performance status (ECOG 0 or 1) was significantly associated with better survival[@B15]. According to this trial, combinations of platinum and those new generation chemotherapeutic agents have been recommended as the first-line treatment of advanced NSCLC, regardless of tumor histology.

In the early 2000s, pemetrexed was introduced as another new generation chemotherapeutic agent with proven efficacy in lung cancer. In the phase 3 JMDB trial, pemetrexed demonstrated pronounced clinical benefit on nonsquamous than squamous cell histology[@B16], which provided the concept that histology does matter in the treatment of lung cancer. Subsequent phase 3 JMEN trial demonstrated the clinical benefit of pemetrexed maintenance treatment in nonsquamous cell carcinoma[@B17]. In that trial, the median OS was significantly higher in patients treated with pemetrexed maintenance after 4-cycled platinum doublet compared with those without maintenance therapy (13.4 months vs. 10.6 months; hazard ratio \[HR\], 0.79; p=0.012)[@B17].

Anti-angiogenesis drugs such as bevacizumab, and new drug delivery systems such as nanoparticle albumin-bound paclitaxel (*nab*-paclitaxel) have also shown clinical benefit in terms of efficacy and tolerability in the middle 2000s and early 2010s, respectively, and have been approved as new valid agents for lung cancer treatment. In recent years, chemotherapy- based combinational approaches using TKIs or ICIs has shown survival benefit over chemotherapy alone[@B18][@B19]. [Figure 1](#F1){ref-type="fig"} summarizes the evolution of chemotherapy-based therapeutic approaches and the progress of clinical benefit according to landmark trials.

Cisplatin versus Carboplatin
============================

Platinum compound indiscriminately attacks all rapidly dividing cells which results in drug-related side effects that include gastrointestinal toxicity, nephrotoxicity, neurotoxicity, ototoxicity, and myelosuppression[@B20]. Compared to cisplatin, carboplatin is slightly less associated with those toxicities except myelosuppression, and is also slightly less efficacious for the treatment of lung cancer[@B20]. In a meta-analysis, cisplatin-based chemotherapy showed a better objective response rate (ORR) (odds ratio \[OR\], 1.36; p\<0.001) without OS benefit (HR, 1.050; p=0.515) compared with carboplatin-based chemotherapy[@B21]. However, subgroup analysis revealed that combinations of cisplatin and new generation agents yield 11% of OS benefit over carboplatin with the same new agents (HR, 1.106; p=0.039)[@B21]. In this analysis, cisplatin-based chemotherapy was more frequently associated with nausea and vomiting (OR, 2.51), but less associated with grade ≥3 thrombocytopenia (OR, 0.58)[@B21]. Based on the previous data, cisplatin combination should be a preferred regimen especially combined with new generation drugs. However, considering the modest OS benefit of cisplatin over carboplatin, and the purpose of chemotherapy in advanced disease where the goal is not cure but symptom and disease control, carboplatin is still a valid option. The choice of platinum compound in practice should be individualized based not only on the patients\' age but also on comorbidities that may be associated with the risk of drugrelated adverse effects.

Optimal Number of Cycles of Platinum-Based Chemotherapy
=======================================================

The ideal number of platinum-based chemotherapy cycles in patients with advanced NSCLC has long been a clinical issue[@B22][@B23]. Guidelines recommend that patient with responsive or stable disease can continue to receive a total of 4 to 6 cycles of first-line systemic chemotherapy, and more than 6 cycles of chemotherapy is not recommended[@B8][@B9][@B10]. A recent meta-analysis using individual patient data compared the survival of the patients who were treated with 3- or 4-cycled- versus 6-cycledfirst-line platinum doublet[@B24]. Modest median progression-free survival (PFS) increase in the group receiving 6 cycles of therapy compared to 3- or 4-cycled group (5.33 months vs. 6.09 months; HR, 0.79; p=0.0007) was observed, however, median OS was not different between the two groups (8.68 months vs. 9.54 months; HR, 0.94; p=0.33)[@B24]. Only 53% of patients completed the intended 6 cycles of chemotherapy, while 80% completed 3 or 4 treatment cycles in that analysis[@B24]. The survival data were similar, regardless of the platinum compounds used which is consistent with previous data[@B15]. Interestingly, the median OS was longer in patients treated with cisplatinbased doublet compared to those treated with carboplatin doublet (10.9 months and 7.0 months respectively, in patients with 3- or 4-cycled treatment)[@B24], which confirmed the previous meta-analysis data[@B21]. Overall, OS difference could not be found between 3- or 4-cycled and 6-cycled platinum-doublet chemotherapy. However, the observations of increased PFS in patients receiving prolonged treatment, despite more frequent adverse events[@B23][@B24], have provided the fundamentals of the concept of "maintenance therapy" beyond 4 or 6 cycles using less toxic agents. This concept was proved by several pivotal trials which will be discussed in the next section.

Maintenance Therapy
===================

The main purpose of maintenance therapy is to improve survival by prolonging tumor response using a well-tolerated drug in patients who have not progressed during first-line treatments. At least one of the agents given in the first-line regimen can be continued, or a different agent that was not included in the first-line regimen can be chosen for maintenance treatment. The former represents continuation maintenance, while the latter represents switch maintenance. These approaches have now become a standard of care in patients with both squamous and nonsquamous NSCLC.

The pioneer in this new treatment strategy is pemetrexed. The clinical benefit of switch maintenance treatment using pemetrexed in patients with nonsquamous NSCLC patients was first demonstrated in the phase 3 JMEN trial[@B17]. The subsequent landmark phase 3 PARAMOUNT trial evaluated the role of pemetrexed as a continuation maintenance treatment in patients without progression after 4 cycles of pemetrexed/cisplatin[@B25]. Both PFS (4.1 months vs. 2.8 months; HR, 0.62; p\<0.0001) and OS (13.9 months vs. 11.0 months; HR, 0.78; p=0.0195) were prolonged in the pemetrexed maintenance group compared to the placebo group[@B25][@B26]. Based on the data of those data, this maintenance strategy was approved by Food and Drug Administration (FDA) at 2009. A subsequent analysis for patients\' quality of life (QoL) during this trial demonstrated similar QoL profiles between both groups[@B27].

In the aforementioned maintenance trials, the study subjects were enrolled regardless of *EGFR* mutational status. As pemetrexed-based doublet is not indicated as a first-line treatment in *EGFR* mutated patients, the clinical benefit of the pemetrexed maintenance treatment over the conventional chemotherapy needs to be re-evaluated for patients without *EGFR* mutations. A recent retrospective study reported survival data on those patients[@B28]. Interestingly, the median OS was significantly longer in the pemetrexed maintenance group (23.3 months vs. 11.0 months, p=0.005), and the OS difference was more pronounced compared with those of previous trials. Current guidelines recommend a continuation maintenance with bevacizumab, pemetrexed, bevacizumab plus pemetrexed (in nonsquamous histology), and gemcitabine (in squamous histology). Switch maintenance with pemetrexed is also recommended in nonsquamous histology. Currently, only pemetrexed continuation maintenance is reimbursed by the National Health Insurance System (NHIS) in Korea.

New Drug Delivery System
========================

Despite chemotherapy has been successfully improved the survival of patients with lung cancer, there are several limitations of conventional chemotherapy: the high rate of adverse events due to nonspecific targeting, and relative short survival compared with targeted therapy or immunotherapy[@B29]. The drug delivery system has been a region of interest to overcome these drawbacks of conventional chemotherapy. This section will cover the two representative systems that are currently recommended or having shown promising data.

1. *Nab*-paclitaxel
-------------------

*Nab*-paclitaxel is an albumin-bound-stabilized nanoparticle formulation of paclitaxel designed to overcome the insolubility of the conventional solvent-based paclitaxel (*sb*-paclitaxel). *Nab*-paclitaxel has the merit that it requires a shorter infusion time (30 minutes vs. 3 hours), and can avoid hypersensitivity reactions, as it is free of Cremophor EL, a solvent for *sb*-paclitaxel[@B30]. While it may be less convenient in that *nab*-paclitaxel should be administered every week rather than every 3 weeks, it may be beneficial in terms of managing or avoiding critical adverse events.

A pivotal phase 3 trial has demonstrated significantly higher ORR and non-inferior PFS and OS of *nab*-paclitaxel/carboplatin compared to *sb*-paclitaxel combination[@B31]. Interestingly, the difference in ORR was more prominent in patients with squamous histology compared with nonsquamous histology. Moreover, the *nab*-paclitaxel arm was associated with a lower rate of grade ≥3 neutropenia, peripheral neuropathy, arthralgia, and myalgia, although it was associated with more grade ≥3 anemia and thrombocytopenia[@B31]. In a subsequent trial, *nab*-paclitaxel/carboplatin combination has shown OS benefit over *sb*-paclitaxel combination in elderly patients over 70 years old[@B32]. This survival benefit seen in elderly patients may be associated with less toxicity and more completion of preplanned treatment. In addition, the weekly dosing schedule of *nab*-paclitaxel might contribute to better treatment efficacy[@B30]. Current guidelines recommend *nab*-paclitaxel/carboplatin combination as a first-line regimen in both squamous and nonsquamous histology[@B8][@B9][@B10]. In particular, the National Comprehensive Cancer Network (NCCN) guideline states that *nab*-paclitaxel may be substituted for either paclitaxel or docetaxel in patients who have experienced hypersensitivity reactions after receiving paclitaxel or docetaxel despite premedication, or where premedications are contraindicated[@B10]. In Korea, *nab*-paclitaxel use has been approved for pancreatic, breast and lung cancer treatment; however to date, its usage for lung cancer is not reimbursed by the NHIS. Given its favorable efficacy and tolerability, *nab*-paclitaxel is a valuable option for a first-line treatment in patients with advanced NSCLC.

2. Antibody drug conjugates
---------------------------

Antibody drug conjugates (ADCs) are one of the targeted drug delivery systems. ADCs are complexes of antibody linked to a biologically active cytotoxic agent to be delivered specifically to cancer cells[@B33]. Two drugs worth mentioning in lung cancer are ado-trastuzumab emtansine for NSCLC, and rovalpituzumab tesirine for small cell lung cancer (SCLC). Adotrastuzumab emtansine is the FDA-approved ADC for human epidermal growth factor receptor 2 (HER2)-positive breast cancer[@B34]. In a recent phase 2 basket trial which included heavily treated *HER2*-mutant NSCLC patients, ado-trastuzumab emtansine showed 44% of response rate (RR), and 5 months of median PFS[@B35]. Toxicities were manageable, and no patient stopped therapy as a result of toxicity[@B35].

Rovalpituzumab tesirine (Rova-T) is an ADC directed against ligand delta-like protein 3 (DLL3), a novel target expressed in patients with SCLC[@B36]. The first phase 1 trial evaluating Rova-T in patients with relapsed or refractory SCLC has reported impressive data: 18% of ORR and 68% of disease control rate (DCR)[@B37]. Intriguingly, high DLL3 expression was associated with high DCR; 88% and 50% in high (\>50%) and low (\<50%) DLL3 groups, respectively. In addition, high DLL3 group showed a significantly longer median PFS (4.3 months) and OS (5.8 months), compared with the overall population[@B37]. Rova-T showed a unique toxicity profile, notable for thrombocytopenia, serosal effusions, and skin reactions. The mechanism of these toxic effects is not clear, but probably relates to the pyrrolobenzodiazepine dimer component of this complex[@B37]. Overall, Rova-T showed encouraging single-agent antitumor activity with a manageable safety profile in patients with relapsed or refractory SCLC. In addition, DLL3 may be a potential predictive marker in this setting. Based on these promising data, several clinical trials investigating Rova-T in SCLC are now ongoing; a phase 3 trial on Rova-T maintenance treatment after 4-cycled platinum-based doublet, and another phase 3 trial comparing Rova-T and topotecan as second-line treatment for relapsed disease[@B38].

Combinational Approach with Other Anti-neoplastic Agents
========================================================

1. Combination with angiogenesis inhibitors
-------------------------------------------

As a monoclonal antibody that binds vascular endothelial growth factor (VEGF)-A, bevacizumab inhibits endothelial cell proliferation and migration which are the critical steps in carcinogenesis. Clinical efficacies of bevacizumab in lung cancer have been proved in several previous trials[@B39][@B40][@B41]. In the phase 3 ECOG4599 trial, bevacizumab (at a dose of 15 mg/kg) combined with paclitaxel/carboplatin has demonstrated significantly clinical benefit in terms of RR (35% vs. 15%, p\<0.001), PFS (6.2 months vs. 4.5 months, p\<0.001), and OS (12.3 months vs. 10.3 months, p=0.003), compared to paclitaxel/ carboplatin alone[@B39]. In Europe, the phase 3 AVAiL trial attempted to confirm the benefit of bevacizumab in combination with cisplatin/gemcitabine at two different doses (7.5 mg/kg and 15 mg/kg)[@B40]. Although significantly better PFS in both doses of bevacizumab was shown, the OS was not different between the two groups[@B42]. The subsequent phase 3 BEYOND trial evaluating the efficacy of the bevacizumab (15 mg/kg) plus carboplatin/paclitaxel combination in a Chinese cohort has demonstrated significant improvements in both PFS (9.2 months vs. 6.5 months; HR, 0.40; p\<0.001) and OS (24.3 months vs. 17.7 months; HR, 0.68; p=0.0154)[@B41]. A metaanalysis also demonstrated significant RR, PFS, and OS benefit of bevacizumab plus platinum-doublet over platinum-doublet alone[@B43]. As bevacizumab was associated with a high rate of life-threatening hemoptysis, tumor adjunct to major blood vessels, cavitary tumors and squamous histology are contraindicated, and bevacizumab plus platinum-doublet is recommended only for nonsquamous histology[@B8][@B13]. This combinational approach has been evaluated in adjuvant setting for surgically resected, early-staged NSCLC, however, it failed to prove OS benefit[@B44].

Ramucirumab, a monoclonal antibody to VEGF receptor 2, and nintedanib, a multiple kinase inhibitor, are another angiogenesis inhibitors with proven survival benefit in the second or later line setting in lung cancer treatment[@B45][@B46]. The phase 3 REVEL trial compared ramucirumab plus docetaxel combination and docetaxel alone in the second-line setting[@B45]. Of note in this trial, patients who previously received bevaciuzumab and those who had squamous histology were not excluded. Modest but statistically significant improvement in OS (10.5 months vs. 9.1 months; HR, 0.86; p=0.023) and PFS (4.5 months vs. 3.0 months; HR, 0.76; p\<0.0001) was shown in combination arm[@B45]. Although, the NCCN guideline recommend use of ramucirumab plus docetaxel combination[@B10], the use of the regimen seems to have not been widely adopted, maybe due to the concern of toxicities and relatively low cost-effectiveness[@B47]. Currently, bevacizumab and platinum doublet combination regimen is approved for the treatment of advanced nonsquamous NSCLC; however, this regimen is not covered by the NHIS in Korea.

2. Combination with targeted therapy
------------------------------------

Although molecular targeted therapy has dramatically improved the survival of *EGFR*-mutated or *ALK*-rearranged NSCLC patients[@B48], it is undeniable that OS benefit is partly attributable to the use of subsequent chemotherapy after TKI failure. From this point of view, the combination of TKI and chemotherapy as a first-line treatment for advanced NSCLC is a feasible approach. The INTACT 1 trial investigated gefitinib plus gemcitabine/cisplatin combination in advanced NSCLC[@B49]. Although there were no significant unexpected adverse events, there was also no clinical benefit in the combination group[@B49]. Another phase 3 trial testing erlotinib plus gemcitabine/cisplatin also failed to prove clinical benefit over the control group[@B50]. In this trial, in only a small never-smoker subgroup, OS and PFS were increased in combination arm[@B50].

FASTACT-2 trial has firstly demonstrated the potential benefit of the chemotherapy plus EGFR-TKI combination in advanced NSCLC[@B18]. In this trial, an intercalated combination of chemotherapy and erlotinib (150 mg/day on days 15--28) was associated with better PFS (16.8 months vs. 6.9 months; HR, 0.25; p\<0.0001) and better OS (31.4 months vs. 20.6 months; HR, 0.48; p=0.0092) over chemotherapy alone in *EGFR*-mutated patients[@B18]. The safety profile was similar between the two groups[@B18]. Despite these positive findings, erlotinib plus chemotherapy combination has not yet been recommended in guidelines, maybe due to the issues of dose schedule, optimal intercalation, and post-study treatments in the trial[@B51]. The clinical benefit of this kind of combinational approach seems to be validated by further trials.

3. Combination with immunotherapy
---------------------------------

Until recently, potential antagonism between chemotherapy and immunotherapy is one of the concerns when considering the chemotherapy and ICI combination. However, there have been a bunch of studies that have supported optimistic data on this kind of combinational strategy. Chemotherapy can modulate tumor to be more susceptible for ICI by releasing tumor-specific antigens, up-regulation of major histocompatibility complex expression, increasing the cytotoxic lymphocyte to regulatory T-cell ratio, and inhibiting myeloid-derived suppressor cells[@B52][@B53][@B54][@B55]. Preclinical studies have also shown a synergistic effect of the chemotherapy and ICI combination[@B56][@B57]. The phase 2 KEYNOTE-021G trial is a proof-of-concept study that demonstrated the superiority of combination of chemotherapy and immunotherapy in advanced NSCLC[@B58]. In this trial, pemetrexed/carboplatin combined with pembrolizumab showed significantly better RR and longer PFS than chemotherapy alone in previously untreated patients with metastatic nonsquamous NSCLC without *EGFR* or *ALK* genomic aberrations irrespective of PD-L1 expression[@B58]. Based on those data, this combination has been granted accelerated approval by the U.S. FDA in May 2017.

The clinical benefit of chemotherapy and ICI combination in the same clinical setting were investigated in the phase 3 KEYNOTE-189 trial in which pemetrexed maintenance treatment was permitted in the control arm[@B19]. Pembrolizumab in combination with pemetrexed/carboplatin showed significant improvement in both PFS (8.8 months vs. 4.9 months; HR, 0.52; p\<0.001) and OS rate at 12 months (69.2% vs. 49.4%; HR, 0.49; p\<0.001)[@B19]. In addition, the clinical benefit was found in all subgroups examined, including those with PD-L1 TPS of less than 1%[@B19]. Considering 41.3% of the patients in the placebo-combination group received ICIs on progression, the HR is quite impressive. Adverse events of grade 3 or higher occurred similarly in both groups (67.2% in the pembrolizumabcombination group and 65.8% in the placebo-combination group), although discontinuation due to adverse event was higher in the pembrolizumab-combination group (13.8%) than in the placebo-combination group (7.9%)[@B19]. The addition of pembrolizumab did not appear to increase the frequency of adverse events that are commonly associated with pemetrexed/carboplatin. Similarly, the incidence of most immune-mediated adverse events was not higher with the pembrolizumab-combination group than that previously observed with pembrolizumab monotherapy[@B4]. In addition, the interim data of KEYNOTE-407 phase 3 trial ([NCT02775435](http://clinicaltrials.gov/ct2/show/NCT02775435)) also demonstrated better response and longer PFS and OS in the pembrolizumab plus carboplatin/paclitaxel (or *nab*-paclitaxel) combination over chemotherapy alone in patients with metastatic squamous cell carcinoma irrespective of PD-L1 expression[@B38]. Taken together, "chemoimmunotherapy" may be a new standard of care for the first-line treatment of advanced NSCLC with manageable safety profile. The results of ongoing trials on the chemoimmunotherapy for NSCLC are eagerly awaited[@B38].

Chemotherapy in Early Lung Cancer
=================================

The survival benefit of adjuvant chemotherapy for earlystaged resected lung cancers has been demonstrated in many previous trials[@B59][@B60][@B61][@B62]. A recent meta-analysis has clearly shown the benefit of chemotherapy after surgical resection (HR, 0.86; p\<0.0001) with an absolute increase in survival of 4% at 5 years[@B63]. The benefit was consistent regardless of chemotherapy regimen or patient subgroups. In patients with T2ab-N0 tumors, adjuvant chemotherapy can be considered in selected patients with high-risk features including poorly differentiated tumors, 4 cm or larger tumor size, visceral pleural involvement, vascular invasion, wedge resection, and unknown lymph node status[@B64].

In patients with completely resected N2 disease, postoperative chemoradiation has provided a survival advantage when compared with chemotherapy alone[@B65]. Postoperative chemoradiation can be either concurrent or sequential depending on the type of resection and lymph node status. The NCCN guideline recommends concurrent chemoradiation for R2 resection, whereas it recommends either sequential or concurrent chemoradiation for R1 resections[@B10]. Chemoradiation has also proved its survival benefit for unresectable stage III NSCLC over radiotherapy alone[@B66][@B67]. Of note, concurrent chemoradiation showed superiority compared to sequential therapy in this setting (16% vs. 10% in 5-year-survival rate, p=0.046)[@B68]. The recommended regimens for chemoradiation are etoposide/cisplatin, vinblastine/cisplatin, paclitaxel/carboplatin (for both squamous and nonsquamous NSCLC), and pemetrexed/cisplatin or pemetrexed/carboplatin (for nonsquamous NSCLC). The phase 3 PROCLAIM trial compared the efficacy and safety of pemetrexed/cisplatin and etoposide/cisplatin followed by consolidation chemotherapy in patients with unresectable stage III nonsquamous NSCLC[@B69]. Both regimens were similar in terms of survival but the pemetrexed/cisplatin regimen was associated with less neutropenia (24.4% vs. 44.5%, p\<0.001), and fewer grade 3 or higher adverse events (64.0% vs. 76.8%, p=0.001). These data suggest that pemetrexed/cisplatin is a valid option for concurrent chemoradiation in this setting.

Potential Biomarkers
====================

The discovery and clinical application of biomarkers is critical not only for early detection of the disease but also for the identification of those patients expected to show the best response to therapy. Despite numerous studies, no biomarker to date has been found to have clinical significance for the prediction of outcomes after platinum-based chemotherapy. The KRAS mutation, although it has shown to be related to the poor survival of NSCLC patients in several studies[@B70][@B71], does not appear to be predictive of chemotherapeutic efficacy[@B72][@B73]. Excision repair cross-complementation group 1 (ERCC1) has been linked with resistance to platinum-based chemotherapy in NSCLC[@B74][@B75]. Low ERCC1 levels are related to increased recurrence in untreated patients after lung resection and are correlated with the prolonged survival of NSCLC patients treated with platinum-based adjuvant and palliative chemotherapy[@B76][@B77][@B78]. However, ERCC1-tailored chemotherapy failed to prove its utility in two prospective randomized trials[@B79][@B80]. Among other potential biomarkers, including ribonucleotide reductase M1, breast cancer 1, class III beta-tubulin, Bax and Fas, none was proven to be useful for the prediction of response or survival in platinum-based chemotherapy[@B81][@B82].

Thymidylate synthase (TS) is the primary target of pemetrexed and its expression has been linked with response to antifolate treatment in various cancers, including gastric, esophageal, and colorectal cancers[@B83][@B84][@B85]. In NSCLC, high TS protein expression is associated with poor prognosis following lung resection[@B86][@B87] and high TS mRNA level is associated with poor response to neoadjuvant pemetrexed/gemcitabine treatment[@B88]. In the phase 3 JMDB trial, the pemetrexed/cisplatin combination showed better survival in patients with nonsquamous histology, whereas the gemcitabine/cisplatin was better in survival in patients with squamous histology[@B16]. The poor response of squamous cell carcinoma to pemetrexed has been thought to be related to the high TS level in this histology[@B89][@B90]. Thus, TS may be a predictive marker in pemetrexed-based chemotherapy. Several previous studies have demonstrated the predictive potential of TS level in this setting[@B91][@B92][@B93]. However, a large biomarker-stratified randomized trial failed to show difference in the response and survival of pemetrexed/cisplatin between TS-negative and TS-positive group[@B94]. In this trial, pemetrexed/cisplatin demonstrated superior RR and PFS than gemcitabine/cisplatin only in the TS-negative group, whereas the clinical outcomes of the two regimens were comparable in the TS-positive group[@B93], which merely confirmed the previous data[@B16]. Overall, evidence is still lacking for TS-guided chemotherapy and further investigations are warranted for better understanding of the clinical implication of TS level in platinum-based chemotherapy.

Chemotherapy for Oncogene-Addicted Lung Cancer
==============================================

Guidelines recommend chemotherapy as a subsequent treatment after TKI failure in oncogene-addictive NSCLC[@B8][@B9][@B10]. Several previous trials comparing TKIs and chemotherapy have shown the clinical benefits of chemotherapy in oncogene-addicted lung cancer. For *ALK*-rearranged NSCLC, the RR was as high as 45% to first-line pemetrexed/cisplatin and 20% to pemetrexed or docetaxel as the second line treatment[@B95][@B96]. In addition, pemetrexed showed favorable activity in some kind of driving mutations including *RET* and *ROS1* fusions[@B97][@B98]. As targeted therapy for those rare driving mutations is currently not readily available, chemotherapy, especially pemetrexed-based, may be an evidence-based feasible option in this setting.

Conclusion
==========

Over the past decades, we have noticed huge progress in lung cancer therapeutics. Although the development in chemotherapy has not been so dramatic compared to that in molecular targeted therapy and immune-oncology, evidence clearly shows that chemotherapy is still an essential part of lung cancer treatment, regardless of stage, histology, mutational subtype, and immunologic status. The introduction of new treatment strategies, including maintenance therapy, new drug delivery systems, and combination with other classes of anti-neoplastic drugs, has demonstrated clear improvement in the survival and/or toxicity, compared to the conventional treatment. In particular, chemoimmunotherapy have provided promising data and it would be a new standard of care for nononcogene-addicted NSCLC. Overall, chemotherapy still works even in this era of precision medicine. Future investigations must be focused on the development of novel chemotherapeutic approaches with high efficacy and less toxicity, and identification of potential predictive or prognostic biomarkers to minimize the toxicity and maximize the efficacy of chemotherapy, by selecting an optimal regimen for the individual patient.
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